Evaluation Of Outcomes And Cost-effectiveness Of Implementing Next Generation Human Papillomavirus (HPV) Vaccination And Associated Primary HPV-based Cervical Cancer Screening Strategies In Australia
Funder
National Health and Medical Research Council
Funding Amount
$697,071.00
Summary
This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new va ....This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.Read moreRead less
Randomised Controlled Trial Of HPV Self-sampling For Improving Participation In Cervical Screening: The IPAP Trial
Funder
National Health and Medical Research Council
Funding Amount
$534,461.00
Summary
Effectiveness of cervical cancer screening relies on maximising participation. Unlike a Pap test, an HPV test may be self-collected and this may overcome some of the barriers to Pap testing. Overseas trials have found higher uptake for HPV self-sampling (between 3-30%) compared with Pap test reminder letters. We will conduct the first randomised trial in Australia comparing home-based HPV self-sampling with a reminder letter, to evaluate whether this improves participation and followup.